文献速递血栓与止血

N8-GP在重型A型血友病初治患者中的免疫原性、安全性和有效性:pathfinder6试验结束结果

The immunogenicity, safety, and efficacy of N8-GP in previously untreated patients with severe hemophilia A: pathfinder6 end-of-trial results.
PubMed 文献 · J Thromb Haemost · 2023-08-18

pathfinder6国际3期试验评估延长半衰期FVIII产品N8-GP在81例重型A型血友病初治患者中的免疫原性、安全性和有效性。中位预防治疗2.9年期间,抑制物发生率为30.0%(高滴度15.7%),中位年化出血率为1.4,止血成功率为87.6%。长期N8-GP预防治疗应答良好,抑制物发生率与既往结果一致。

要点

  • 81例初治患者接受N8-GP预防治疗,中位预防时长2.9年,抑制物发生率30.0%,高滴度抑制物15.7%。
  • 预防治疗期间中位年化出血率为1.4,13%患者无出血,55.1%患者无自发性出血。
  • 出血事件止血成功率为87.6%,暂时性增量回收率下降患者无持久临床影响或安全担忧。

核心结论

  • 长期试验结束的初治患者N8-GP预防治疗数据表明,初治患者对长期N8-GP治疗应答良好,抑制物发生率与既往结果一致。
  • 预防治疗期间中位年化出血率为1.4,暂时性增量回收率下降患者无持久临床影响或安全担忧。

研究设计与样本

  • pathfinder6(NCT02137850)为国际3期试验,评估延长半衰期FVIII产品N8-GP(turoctocog alfa pegol;Esperoct)在重型A型血友病初治患者中的免疫原性、安全性和有效性。
  • 共81例患者接受N8-GP并纳入分析,预防方案为约60 IU/kg N8-GP静脉给药,每周两次,或每3天或每7天一次。
  • 主要终点为FVIII抑制物发生率,试验结束结果涵盖中位(范围)2.5(0.0;7.4)年的延长治疗。

主要发现

  • 延长治疗阶段抑制物发生率为30.0%,其中高滴度(>5 BU)抑制物发生率为15.7%。
  • 预防治疗期间中位(四分位距)年化出血率为1.4(0.6;3.5),13%患者无出血事件,55.1%患者无自发性出血。
  • 预防治疗第一年后无自发性出血事件的患者比例增加。
  • 出血事件治疗止血成功率为87.6%。
  • 既往报告暂时性增量回收率下降的患者中未观察到额外安全性问题。

关键数值与推荐

  • 预防方案为约60 IU/kg N8-GP静脉给药,每周两次,或每3天或每7天一次。
  • 主要终点为FVIII抑制物发生率,延长治疗阶段抑制物发生率为30.0%,高滴度(>5 BU)抑制物发生率为15.7%。
  • 预防治疗期间中位年化出血率为1.4(四分位距0.6;3.5),13%患者无出血事件,55.1%患者无自发性出血。
  • 出血事件止血成功率为87.6%。

临床怎么用

  • 长期试验结束的初治患者N8-GP预防治疗数据表明,初治患者对长期N8-GP治疗应答良好,抑制物发生率与既往结果一致。
  • 预防治疗期间中位年化出血率为1.4,暂时性增量回收率下降患者无持久临床影响或安全担忧。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The pathfinder6 (NCT02137850) international phase 3 trial examined immunogenicity, safety, and efficacy of the extended half-life factor VIII (FVIII) replacement product N8-GP (turoctocog alfa pegol; Esperoct) in previously untreated patients (PUPs) with hemophilia A. OBJECTIVES: We present end-of trial results for extended PUP N8-GP treatment for up to a median (range) 2.5 (0.0; 7.4) years. PATIENTS/METHODS: Longer-term N8-GP treatment in PUPs with hemophilia A was examined. The prophylaxis regimen was ∼60 IU/kg N8-GP i.v. twice weekly, or every 3 or 7 days. The primary endpoint was the incidence of FVIII inhibitors. RESULTS: Overall, 81 patients received N8-GP and were included in this analysis. The inhibitor incidence was 30.0% (15.7% high-titer [>5 BU]) for the extension phase. Patients had a median (range) 2.9 (0.1; 7.2) years of prophylaxis following the pre-prophylaxis period. During prophylaxis, the median annualized bleeding rate (ABR) (interquartile range) was 1.4 (0.6; 3.5), 13% of patients experienced no bleeding episodes, and 55.1% of patients experienced no spontaneous bleeds. The proportion of patients without any spontaneous bleeding episodes increased after the first year of prophylaxis. The hemostatic success rate in the treatment of bleeding episodes was 87.6%. No additional safety concerns were observed in patients with previously reported observation of temporarily decreased incremental recovery (IR). CONCLUSION: Long-term end-of-trial PUP N8-GP prophylaxis data indicate that PUPs respond well to long-term N8-GP treatment. The inhibitor incidence was consistent with previous results. Median ABR during prophylaxis was 1.4. There were no lasting clinical impacts or safety concerns for patients with an observation of temporarily decreased IR.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Kenet G, Young G, Chuansumrit A, et al. The immunogenicity, safety, and efficacy of N8-GP in previously untreated patients with severe hemophilia A: pathfinder6 end-of-trial results. J Thromb Haemost. 2023. PMID: 37597724. doi:10.1016/j.jtha.2023.07.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。